Organon & Co.
XTRA:7XP Stock Report
Organon Balance Sheet Health
Financial Health criteria checks 1/6 Organon has a total shareholder equity of $48.0M and total debt of $8.7B, which brings its debt-to-equity ratio to 18154.2%. Its total assets and total liabilities are $11.9B and $11.8B respectively. Organon's EBIT is $1.3B making its interest coverage ratio 2.6. It has cash and short-term investments of $575.0M.
Key information
18,154.2%
Debt to equity ratio
Interest coverage ratio 2.6x Cash US$575.00m Equity US$48.00m Total liabilities US$11.84b Total assets US$11.89b
Recent financial health updates
Show all updates
Organon & Co. Updates on FDA Review of VTAMA (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older Nov 05 Organon & Co. Revises Earnings Guidance for the Full Year 2024
Organon & Co. (NYSE:OGN) completed the acquisition of Dermavant Sciences Ltd. from Roivant Sciences Ltd. (NasdaqGS:ROIV) and others. Oct 28
Organon & Co. to Report Q3, 2024 Results on Oct 31, 2024 Oct 09
Shanghai Henlius Biotech, Inc. and Organon Announces Phase 3 Comparative Clinical Study of Perjeta®? (pertuzumab) Biosimilar Candidate HLX11 Oct 01 Organon & Co. (NYSE:OGN) agreed to acquire Dermavant Sciences Ltd. from Roivant Sciences Ltd. (NasdaqGS:ROIV) and others for approximately $1.2 billion. Sep 18
Organon & Co. Affirms Revenue Guidance for the Full Year 2024
Organon & Co. to Report Q2, 2024 Results on Aug 06, 2024 Jul 10
Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications (Maas) for Hlx14 May 25 Organon & Co. Provides Earnings Guidance for the Year 2023
Organon & Co., Annual General Meeting, Jun 04, 2024 Apr 28
Organon & Co. to Report Q1, 2024 Results on May 02, 2024 Apr 09 US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary
Fourth quarter dividend of US$0.28 announced Feb 18
Organon & Co. Provides Earnings Guidance for the Year 2024 Feb 16 Organon & Co. Declares Quarterly Dividend, Payable on March 14, 2024
Organon & Co. to Report Q4, 2023 Results on Feb 15, 2024 Feb 02
Investor sentiment improves as stock rises 21% Jan 12
Organon’S Xaciato (Clindamycin Phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis in Females Aged 12 and Older Jan 10 Organon & Co. Announces Departure of Sandra Milligan as Head of Research and Development Effective January 5, 2024 Dec 06
Investor sentiment deteriorates as stock falls 31% Nov 29
Samsung Bioepis & Organon Announces FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (Adalimumab-bwwd) Nov 09
Samsung Bioepis & Organon Announces FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (Adalimumab-bwwd) Nov 08
Organon & Co. Declares a Quarterly Dividend, Payable on December 14, 2023 Nov 04
Organon & Co. Declares a Quarterly Dividend, Payable on December 14, 2023 Nov 03
Third quarter 2023 earnings released: EPS: US$0.23 (vs US$0.89 in 3Q 2022) Nov 03 Organon & Co. to Report Q3, 2023 Results on Nov 02, 2023 Oct 20
Financial Position Analysis
Short Term Liabilities: 7XP's short term assets ($4.2B) exceed its short term liabilities ($2.5B).
Long Term Liabilities: 7XP's short term assets ($4.2B) do not cover its long term liabilities ($9.3B).
Debt to Equity History and Analysis
Debt Level: 7XP's net debt to equity ratio (16956.3%) is considered high .
Reducing Debt: 7XP's debt to equity ratio has increased from 2.4% to 18154.2% over the past 5 years.
Debt Coverage: 7XP's debt is not well covered by operating cash flow (8.7%).
Interest Coverage: 7XP's interest payments on its debt are not well covered by EBIT (2.6x coverage).
Discover healthy companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":false,"variant":{"name":"disabled","enabled":false},"flagsReady":false,"flagsError":null}